Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques
Statin treatment in patients with coronary heart disease is associated with a reduced incidence of short-term adverse events and endpoint cardiac events . However , the effects of statin treatment on atherosclerotic plaques , particularly stable plaques , remain poorly defined . In total , 228 consecutive patients with stable atherosclerotic plaques who had undergone coronary arteriography ( CAG ) and intravascular ultrasound ( IVUS ) were r and omly assigned to receive placebo ( placebo group , n=54 ) or atorvastatin ( ATOR ) at a single daily dose of 10 mg ( ATOR 10 mg group , n=47 ) , 20 mg ( ATOR 20 mg group , n=45 ) , 40 mg ( ATOR 40 mg group , n=43 ) or 80 mg ( ATOR 80 mg group , n=39 ) . Endpoints , including serum lipids , serum inflammation , plaque volume and percentage of plaque necrosis were assessed after 3–6 months . At baseline , mean low-density lipoprotein ( LDL ) , high-density lipoprotein ( HDL ) and high-sensitivity C-reactive protein ( hs-CRP ) levels , as well as plaque volumes and percentages of plaque necrosis , were similar between all groups . At 6 months of follow-up , the LDL levels in the ATOR groups were below those at their respective baselines ( P<0.01 ) . HDL levels in the ATOR 80 mg group following treatment were significantly higher compared with baseline ( P=0.001 ) . Additionally , they were significantly higher compared with those in the placebo , ATOR 10 , 20 and 40 mg groups ( P<0.01 , P=0.001 , P=0.048 , P=0.047 , respectively ) . Hs-CRP levels in the placebo group following treatment were higher compared with baseline levels ( 6.87±2.62 vs. 5.07±1.80 , P<0.01 ) , but hs-CRP levels in the ATOR 80 mg group following treatment were lower compared with baseline ( 3.59±1.07 vs. 6.10±2.12 , P<0.01 ) . According to the virtual histology ( VH ) of IVUS , the percentages of plaque necrosis following treatment in the placebo and ATOR 10 mg groups rose above baseline levels ( 15.51±12.56 vs. 7.69±1.31 % , 13.54±11.76 vs. 7.83±1.43 % , P<0.01 ) and conformed to the diagnostic criteria for unstable plaques ( 15.51±12.56 , 13.54±11.76 % ) . By contrast , in the ATOR 20 , 40 and 80 mg groups , percentages of plaque necrosis remained stable following treatment compared with baseline ( P=0.069 , 0.846 and 0.643 , respectively ) . Plaque volumes following treatment in the placebo , ATOR 10 and 20 mg groups were similar to baseline levels . However , in the ATOR 40 and 80 mg groups , plaque volumes decreased following treatment compared with baseline plaque volumes ( 30.69±8.12 vs. 37.09±12.01 mm3 , 24.99±1.01 vs. 36.47±14.68 mm3 , P=0.019 , P<0.01 , respectively ) . ATOR ( 20 mg/day ) is able to lower LDL to st and ard levels while ATOR 40 mg/day was superior to 20 mg/day and had similar effects to 80 mg/day . Only ATOR 80 mg/day was able to increase HDL levels . Hs-CRP in patients without ATOR was higher and ATOR 80 mg/day decreased levels . ATOR ≥20 mg/day is able to stabilize plaques and ATOR 80 mg/day was superior to 20 and 40 mg/day . Thus , ATOR 40–80 mg/day reduces the volume of plaques
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .